Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Christina Rolling: CAR T-Cell Therapy and Coagulation Disturbances Understanding Severe Hypofibrinogenemia
Nov 19, 2026, 10:08

Christina Rolling: CAR T-Cell Therapy and Coagulation Disturbances Understanding Severe Hypofibrinogenemia

Christina Rolling, Specialist in Internal Medicine and Hematology and Oncology at University Medical Center Hamburg-Eppendorf, shared a post on LinkedIn about a recent article, she and her colleagues co-authored, published in Haematologica, adding:

“Excited to share our new publication on coagulation disturbances in patients undergoing CAR T-cell therapy!

We found that severe hypofibrinogenemia (fibrinogen lower 1 g/L) is a frequent finding, particularly in patients with lymphoma receiving tocilizumab for cytokine release syndrome (CRS).

Both increased fibrinogen consumption due to coagulation activation and reduced fibrinogen synthesis following IL-6 receptor blockade may contribute to CAR T-cell therapy-associated hypofibrinogenemia.

Interestingly, among patients with non-Hodgkin lymphoma receiving axi-cel, higher peak CAR T-cell levels were associated with lower fibrinogen nadirs and greater CRS severity.

This was a fantastic team effort! A huge thank you to everyone involved for the excellent collaboration!”

Title: Dynamics and clinical significance of coagulation abnormalities following CAR T-cell therapy

Authors: Christina Charlotte Rolling, Nigar Mammadova, Catherina Lück, Rolf Krause, Lennart Beckmann, Jochim Reinert, Carolina Berger, Boris Fehse, Florian Langer, Francis Ayuk

Christina Rolling: CAR T-Cell Therapy and Coagulation Disturbances Understanding Severe Hypofibrinogenemia

Stay updated with Hemostatis Today.